Silodosin Capsule
Product Images NDC 62332-405

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Silodosin (NDC 62332-405). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

30 Capsues In 1 Bottle (Silodosin 4mg)

Label for Silodosin 4 mg capsules by Alembic Pharmaceuticals Inc. The label states the product strength as 4 mg per capsule and the package contains 30 capsules. Storage instructions indicate keeping at controlled room temperature (25°C, with permitted excursions). The label includes the NDC 62332-405-30, manufacturer details (Alembic Pharmaceuticals Limited, India and Alembic Pharmaceuticals, Inc. USA), and directions to take 1 capsule daily with a meal.*

FDA Label Image

30 Capsules (Silodosin 8mg)

Label for Silodosin 8 mg capsules, oral dosage form. The label shows the product name, strength (8 mg per capsule), and quantity (30 capsules). It includes storage instructions, manufacturer information (Alembic Pharmaceuticals Limited and Alembic Pharmaceuticals Inc.), a barcode, and an NDC number 62332-406-30. The label states 'Rx only' and provides usage directions.*

FDA Label Image

Figure 1 (Silodosin Figur1)

A line graph showing Silodosin concentration (ng/mL) over time in hours. Concentration rises sharply from 0 to about 4 hours, peaking near 45 ng/mL, then gradually declines over 24 hours. Error bars indicate variability at each time point.*

FDA Label Image

Figure 2 (Silodosin Figur2)

A line graph comparing the change from baseline in IPSS total score over time between Placebo and Silodosin Capsules 8 mg. The x-axis represents days (Baseline, 3.5, 7, 14, 28, 84/LOCF) and the y-axis shows change from baseline. The graph shows Silodosin Capsules 8 mg with a greater decrease in score compared to Placebo, indicating a larger effect over the 84-day period.*

FDA Label Image

Figure 3 (Silodosin Figur3)

A line graph comparing the change from baseline in IPSS Total Score over time between Silodosin Capsules 8 mg and placebo. The x-axis represents days (Baseline, 3.5, 7, 14, 28, and 84/LOCF), and the y-axis shows change from baseline score, with Silodosin showing a greater decrease than placebo, indicating improvement over the study period.*

FDA Label Image

Figure 4 (Silodosin Figur4)

A line graph comparing change from baseline in Qmax (mL/sec) over time (days) between Silodosin Capsules 8 mg and placebo. The graph shows Silodosin with a higher and sustained increase in Qmax compared to placebo, with data points at baseline, day 1, 7, 14, 28, and 84/LOCF. Statistical significance is indicated at some points (p<0.05).*

FDA Label Image

Figure 5 (Silodosin Figur5)

A line graph showing the change from baseline in Qmax (mL/sec) over days for Silodosin Capsules 8 mg compared to placebo. The graph plots data points from baseline to day 84, with Silodosin maintaining a higher increase in Qmax than placebo throughout the period, and statistical significance indicated at certain time points.*

FDA Label Image

Structure (Silodosin Structure)

Chemical structure of Silodosin, showing its molecular framework with aromatic rings, functional groups including amide and hydroxyl, and a trifluoromethyl group, consistent with its identity as the active ingredient in Silodosin capsules.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.